244 results on '"Lofland, Jennifer"'
Search Results
2. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
3. Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016
4. Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis
5. Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient‐Reported Outcomes and Treatment: Analysis of Real‐World Data
6. Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
7. Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis
8. The Employee Absenteeism Costs of Rheumatoid Arthritis : Evidence From US National Survey Data
9. Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making
10. The Employee Absenteeism Costs of Inflammatory Bowel Disease : Evidence From US National Survey Data
11. Additional file 1 of Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016
12. Gastroenterologists’ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease
13. Impact of Topiramate Migraine Prophylaxis on Workplace Productivity: Results from Two US Randomized, Double-Blind, Placebo-Controlled, Multicenter Trials
14. Effect of Health Insurance on Workplace Absenteeism in the U.S. Workforce
15. Health-Related Workplace Productivity Measurement: General and Migraine-Specific Recommendations from the ACOEM Expert Panel
16. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
17. Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus
18. Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
19. Update on Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE) by Major Health Insurance Types in the US
20. Oral serotonin receptor agonists: A review of their cost effectiveness in migraine
21. A Review of Health-Related Workplace Productivity Loss Instruments
22. Migraine Prophylaxis in Managed Care Organizations: Unclear Role in Disease Management Programs
23. Different Approaches To Valuing the Lost Productivity of Patients with Migraine
24. Pharmacoeconomic Fellowships: The Need for Outcome Measures
25. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus
26. Opioid Use in Patients With Inflammatory Bowel Disease
27. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States
28. The role of the pharmacist in disease management
29. Pharmacy practice and health policy within the U.S.
30. Workplace Absenteeism and Aspects of Access to Health Care for Individuals With Migraine Headache: CME
31. Effects of a Website Designed to Improve the Management of Migraines
32. Outcome Measures for Pharmacoeconomics Education
33. Reliability and Validity of the Migraine Therapy Assessment Questionnaire
34. Publicly available US national surveys that capture lost productivity
35. Sumatriptan Use in Patients With Migraine
36. Cost-Effectiveness and Cost-Benefit of Sumatriptan in Patients With Migraine
37. Quality-of-Life Differences Between Patients With Episodic and Transformed Migraine
38. Changes in Resource Use and Outcomes for Patients With Migraine Treated With Sumatriptan: A Managed Care Perspective
39. FRI0201 REAL WORLD MEDICATION USE IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS PATIENTS
40. FRI0178 CLUSTER PROFILING OF PATIENTS IN A REAL-WORLD DATA SET WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR ASSOCIATED TREATMENTS
41. FRI0256 ASSESSING THE PREVALENCE AND USE OF VALIDATED SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY METRICS IN REAL WORLD PRACTICE
42. AB0486 LACK OF CONSISTENT STANDARD OF CARE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN REAL WORLD
43. Cost comparison of computerized touch-screen technology and traditional paper systems for evaluating quality of life outcomes.: 67.
44. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis
45. Opioid Use in Patients With Inflammatory Bowel Disease.
46. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
47. Sa1811 - Opioid use in Patients with Inflammatory Bowel Disease
48. Medical outcomes study short form 36: A possible source of utilities?
49. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs
50. Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.